Skip to main content
      RT @RichardPAConway: Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and M

      Richard Conway RichardPAConway

      3 years 10 months ago
      Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and MTX. But more AEs when MTX without folic acid 32 vs 16% - nausea, transaminase elevations. @RheumNow #ACR22 Abstr#0930 https://t.co/jsUYG2YIZL https://t.co/YOpUbA4Ze9
      RT @synovialjoints: IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study
      ◦ improveme

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study ◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline ◦ associated with improved BASFI, fatigue, SF36 Ramiro S Abs1009 https://t.co/GiCqg7W9IR #ACR22 @RheumNow
      RT @JulianSegan: Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dos

      Julian Segan JulianSegan

      3 years 10 months ago
      Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dose-dependent increase in risk. Agents include quartz, asbestos, fungicides & carbon monoxide. This is a common pt question! @RheumNow ABST0601 #ACR22 https://t.co/QbsSLIXNar
      RT @RichardPAConway: Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. High

      Richard Conway RichardPAConway

      3 years 10 months ago
      Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. Higher flare rate with 2 week hold. @RheumNow #ACR22 Abstr#0936 https://t.co/G53mcWFK2C https://t.co/VFY9TS5OIv
      RT @ericdeinmd: Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs
      P Mease on BE MOBILE 1 & 2
      BKZ 160 mg q4w vs PBO

      Eric Dein ericdeinmd

      3 years 10 months ago
      Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs P Mease on BE MOBILE 1 & 2 BKZ 160 mg q4w vs PBO 254 pts w nr-axSpA, 332 w AS Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16 @RheumNow https://t.co/nxZFSrb2XK
      RT @ericdeinmd: Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA
      31 CBTT courses in 29 SpA pts - 69% al

      Eric Dein ericdeinmd

      3 years 10 months ago
      Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA 31 CBTT courses in 29 SpA pts - 69% also w IBD Most common: TNF+IL12/23 or IL17 12 pts (38%) d/c CBTT - 7 inefficacy (5 2/2 IBD), 2 for AEs, 3 for other causes. 2 serious AEs (pulm infiltrates, staph ifn) @RheumNow https://t.co/zExkpam0zK
      RT @RichardPAConway: Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease.

      Richard Conway RichardPAConway

      3 years 10 months ago
      Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease. No significant difference. But 59% vs 32% for irAEs and 23% vs 10% for high grade irAEs @RheumNow #ACR22 Abstr#0757 https://t.co/UYhRM4xO9r https://t.co/r4NurxXzGZ
      RT @RichardPAConway: Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All

      Richard Conway RichardPAConway

      3 years 10 months ago
      Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All forms progesterone appears equally safe (differs ACR guidance which does not recommended IM or implant) @RheumNow #ACR22 Abstr#0943 https://t.co/HGuZJgaRZQ https://t.co/KrIaKaYNTy
      New Treatments for SLE?
      RT @drdavidliew: It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials.

      A compell

      David Liew drdavidliew

      3 years 10 months ago
      It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials. A compelling bench-to-bedside story by @MdWarrington, Dr. Weyand, Dr. Koster and team, and definitely a space to watch #ACR22 @RheumNow https://t.co/2acKFrWOUF
      RT @EBRheum: "You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis"

      Mike Putman EBRheum

      3 years 10 months ago
      "You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis" -John Stone #ACR22 @RheumNow
      RT @Janetbirdope: Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help

      Janet Pope Janetbirdope

      3 years 10 months ago
      Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest ⁦@RheumNow⁩ #ClinicalPearl https://t.co/S8fHi7dFoD
      ×